bosentan anhydrous has been researched along with Heritable Pulmonary Arterial Hypertension in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 64 (90.14) | 24.3611 |
| 2020's | 7 (9.86) | 2.80 |
| Authors | Studies |
|---|---|
| Alotaibi, M; Fernandes, TM; Hoang, HB; Kim, NH; Lombardi, S; Papamatheakis, DG; Poch, DS; Rodriguez, C; Wu, S; Yang, JZ | 1 |
| Ceriani, F; Cosentino, M; De Ponti, R; Ferrari, M; Imporzani, A; Lattanzio, M; Marino, F; Martini, S | 1 |
| Kuno, T; Matsuzaki, Y; Shirasu, T; Sumitomo, N; Takagi, H; Watanabe, A; Watanabe, H; Watanabe, K; Yasuhara, J | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Chen, M; Du, HA; Kuang, HY; Li, Q; Yin, YH | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Aleevskaya, AM; Martynyuk, TV | 1 |
| Apitz, C; Schranz, D | 1 |
| Kuang, HY; Lu, TW; Shou, WN; Tian, J; Wu, C; Wu, YH; Yi, QJ | 1 |
| Dai, HL; Guang, XF; Lu, YB; Xiao, ZC; Zhang, M; Zhang, WH | 1 |
| Antonova, OIu; Arkhipova, OA; Chazova, IE; Kobal', EA; Martyniuk, TV; Masenko, VP; Rvacheva, AV; Zykov, KA | 1 |
| Humbert, M; Jardim, C; Souza, R | 1 |
| Bonilla-Palomas, JL; Gámez-López, AL; López-Ibáñez, MC; Moreno-Conde, M; Villar-Ráez, A | 1 |
| Cam, H; Dag, MS; Davutoglu, V; Durmus, E; Kivrak, T; Sari, I; Tigen, K | 1 |
| Hoenicka, M; Hofmann, HS; Liebold, A; Neu, R; Potzger, T; Ried, M; Sziklavari, Z; Szöke, T | 1 |
| Lee, YH; Song, GG | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Romaniello, A; Rosato, E; Salsano, F; Viola, G | 1 |
| Bartelds, B; Berger, RM; Douwes, JM; Hillege, HL; Ploegstra, MJ; Roofthooft, MT; Van Loon, RL | 1 |
| Kanda, T; Naito, A; Sakao, S; Sugiura, T; Tanabe, N; Tatsumi, K; Terada, J; Yokosuka, O | 1 |
| Morrell, NW; Pepke-Zaba, J; Sheares, K; Soon, E; Southwood, M | 1 |
| Cleary, KL; Običan, SG | 1 |
| Albini, A; Bacchi Reggiani, ML; Bachetti, C; Dardi, F; Galiè, N; Gotti, E; Manes, A; Mazzanti, G; Monti, E; Palazzini, M; Rinaldi, A | 1 |
| Rubin, LJ; Vachiery, JL | 1 |
| Beghetti, M; Berger, RM; Bonnet, D; Dulac, Y; Efficace, M; Fraisse, A; Galiè, N; Haworth, SG; Ivy, DD; Jaïs, X; Kusic-Pajic, A; Miera, O; Rosenzweig, EB | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Dalton, B; Gabbay, E; Keogh, A; McNeil, K; Proudman, S; Strange, G; Weintraub, RG; Williams, TJ; Wlodarczyk, J | 1 |
| de Boer, MA; Mouchaers, KT; Postmus, PE; Schalij, I; van der Laarse, WJ; van Hinsbergh, VW; van Nieuw Amerongen, GP; Vonk Noordegraaf, A | 1 |
| Argiento, P; Calabrò, R; Correra, A; D'Alto, M; Grimaldi, N; Romeo, E; Russo, MG; Santoro, G; Sarubbi, B; Scognamiglio, G | 1 |
| Brown, K; Dalton, B; Gabbay, E; Keogh, A; Kermeen, F; Kilpatrick, D; Kotlyar, E; Macdonald, P; Pidoux, A; Steele, P; Strange, G; Williams, T | 1 |
| Adams, MR; Celermajer, DS; Ilsar, R; Kritharides, L; Levitt, J; Ng, MK | 1 |
| Chang, SA; Jang, SY; Kang, IS; Ki, CS; Kim, DK | 1 |
| Foster, H; Haworth, SG; Hislop, AA; Moledina, S; Schulze-Neick, I | 1 |
| Derk, CT; Shetty, N | 1 |
| Arkhipova, OA; Ataullakhanova, DM; Chazova, IE; Danilov, NM; Lazutkina, VK; Martyniuk, TV; Samoĭlenko, LE; Stukalova, OV | 1 |
| Akita, C; Hashimoto, Y; Hirono, K; Horiuchi, I; Ichida, F; Kato, Y; Miyawaki, T; Nakamura, T; Nakayama, T; Saji, T; Taguchi, M; Yoshimura, N | 1 |
| Davie, N; Hall, SM; Haworth, SG; Klein, N | 1 |
| Dai, LZ; Jiang, X; Jing, ZC; Wang, GY; Wang, Y; Wu, BX; Yao, H; Yu, ZX | 1 |
| Kaneko, H; Mimori, A; Takahashi, Y; Ueda, Y; Yamashita, H | 1 |
| Alonso-Pulpón, L; Avellana, P; García-Cosío Carmena, MD; García-Pavía, P; Gómez-Bueno, M; Gutiérrez Landaluce, C; Pérez Pereira, E; Segovia, J; Sufrate, E | 1 |
| Berger, RM; Bouma, BJ; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Mulder, P; van Dijk, AP; Vis, JC | 1 |
| Andreassen, AK; Gude, E; Solberg, OG; Ueland, T | 1 |
| Bouma, BJ; Budts, W; Celermajer, D; Cordina, R; Gatzoulis, MA; Mulder, BJ; Mullen, MP; Schuuring, MJ; Vis, JC | 1 |
| Argiento, P; Bossone, E; Calabrò, R; Correra, A; D'Alto, M; D'Andrea, A; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Scognamiglio, G; Vizza, CD | 1 |
| Hatano, M; Hirata, Y; Kinugawa, K; Nagai, R; Yao, A | 1 |
| French, B; Gabler, NB; Halpern, SD; Kawut, SM; Liu, Z; Palevsky, HI; Strom, BL; Taichman, DB | 1 |
| Brasch, F; Bucher, B; Casaulta, C; Griese, M; Navarini, S; Pavlovic, M; Pfammatter, JP; Regamey, N | 1 |
| Imanishi, J; Miwa, Y; Shimizu, M; Takano, T | 1 |
| Hamidi, SA; Jiang, YP; Lin, RZ; Lyubsky, S; Said, SI; Szema, AM | 1 |
| Franklin, WJ; Parekh, DR; Safdar, Z | 1 |
| Aberer, E; Brodmann, M; Graninger, W; Hesse, C; Kovacs, G; Kqiku, X; Maier, R; Olschewski, H; Rubin, L; Scheidl, S; Tröster, N | 1 |
| Gatzoulis, MA | 1 |
| Hoeper, MM | 1 |
| Humbert, M; Jaïs, X; Kemp, K; Montani, D; O'Callaghan, DS; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Badagliacca, R; Fedele, F; Gambardella, C; Iacoboni, C; Letizia, C; Mancone, M; Marcon, S; Nona, A; Papa, S; Pezzuto, B; Poscia, R; Riccieri, V; Vizza, CD; Volterrani, M | 1 |
| Chatelus, E; Cinquetti, G; Gottenberg, JE; Javier, RM; Ronde-Oustau, C; Sibilia, J; Sordet, C | 1 |
| Huang, XM; Yu, YP | 1 |
| Couderc, LJ; Metivier, AC; Rivaud, E; Tcherakian, C; Zucman, D | 1 |
| Adams, MR; Bailey, BP; Celermajer, DS; Ilsar, R; Iyer, N; Lau, EM | 1 |
| Brady, D; Calderbank, M; Ivy, DD; Rosenzweig, EB; Takatsuki, S; Zuckerman, W | 1 |
| Allen, RP; Arneson, C; Badesch, DB; Frantz, RP; Frost, AE; Galiè, N; Keogh, AM; Kermeen, F; Laliberte, K; Shapiro, SM; Sigman, J; Tapson, VF; Torres, F | 1 |
| Athanassopoulos, GD; Demerouti, EA; Karatasakis, GT; Leontiadis, ED; Manginas, AN; Pavlides, GS | 1 |
| Barst, RJ; Beardsworth, A; Botros, FT; Brundage, BH; Chan, M; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G | 1 |
| Blenkhorn, F; Eisenberg, MJ; Fox, B; Hirsch, AM; Joyal, D; Langleben, D; Lesenko, L; Schlesinger, RD | 1 |
| Fedele, F; Pezzuto, B; Rubin, LJ; Vizza, CD | 1 |
| Rubin, LJ | 1 |
| Luo, N; Ryan, JJ | 1 |
| Clozel, M; Gatfield, J; Mueller Grandjean, C; Nayler, O; Sasse, T | 1 |
| McLaughlin, VV | 1 |
| Cardarelli, S; Cozzi, F; Favaro, M; Pigatto, E; Punzi, L; Riato, L; Rizzo, M; Zanatta, E | 1 |
| Baptista, R; Castro, G; da Silva, AM; Monteiro, P; Providência, LA | 1 |
11 review(s) available for bosentan anhydrous and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Interactions; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension | 2022 |
Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Network Meta-Analysis; Pulmonary Arterial Hypertension; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2023 |
Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Exercise; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Hemodynamics; HIV Infections; Humans; Observational Studies as Topic; Pulmonary Arterial Hypertension | 2021 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Bosentan; Child; Child, Preschool; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Humans; Infant; Middle Aged; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arterial Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Liver; Liver Function Tests; Odds Ratio; Pulmonary Artery; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
Pulmonary arterial hypertension in pregnancy.
Topics: Anesthesia, Obstetrical; Bosentan; Carbolines; Directive Counseling; Epoprostenol; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Iloprost; Infant, Newborn; Piperazines; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pregnancy, High-Risk; Prognosis; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2011 |
[Progress in pharmacotherapy of pulmonary arterial hypertension in children].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Bosentan; Calcium Channel Blockers; Child; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Sulfonamides | 2012 |
Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
Topics: Acenocoumarol; Anticoagulants; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents; Withholding Treatment | 2013 |
Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Bosentan; Drug Design; Drug Monitoring; Endothelin Receptor Antagonists; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sulfonamides | 2012 |
10 trial(s) available for bosentan anhydrous and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
[Effect of bosentan on the clinical status and cellular immunity of patients with idiopathic pulmonary hypertension].
Topics: Adult; Antihypertensive Agents; Bosentan; Echocardiography; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Immunity, Cellular; Male; Prospective Studies; Sulfonamides; T-Lymphocytes; Treatment Outcome; Vascular Resistance | 2013 |
FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.
Topics: Administration, Oral; Adult; Biomarkers, Pharmacological; Bosentan; Dose-Response Relationship, Drug; Drug Tolerance; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Global Health; Humans; Male; Sulfonamides; Survival Rate; Time Factors; Treatment Outcome | 2016 |
Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
Topics: Administration, Oral; Adult; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eisenmenger Complex; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Piperazines; Prospective Studies; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Time Factors; Treatment Outcome; Vascular Resistance | 2012 |
[The efficacy and safety of bosentan therapy for Chinese patients with idiopathic pulmonary arterial hypertension: an open-label, prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Asian People; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Young Adult | 2011 |
Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Pulmonary Artery; Pulmonary Wedge Pressure; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vascular Resistance; Young Adult | 2011 |
Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Ethnicity; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Phenylpropionates; Prevalence; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Sex Factors; Sulfonamides; Thiophenes; Treatment Outcome; United States; Walking; Young Adult | 2012 |
Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Exercise Test; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Middle Aged; Pilot Projects; Scleroderma, Systemic; Sulfonamides; Treatment Outcome | 2012 |
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Walking; Young Adult | 2012 |
Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Sulfonamides; Tadalafil; Treatment Outcome; Vasodilator Agents | 2012 |
50 other study(ies) available for bosentan anhydrous and Heritable Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report.
Topics: Bosentan; Counseling; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Arterial Hypertension; Receptors, Epoprostenol; Transaminases | 2022 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
[Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrimidines; Retrospective Studies; Russia; Sulfonamides; Treatment Outcome | 2020 |
Sildenafil-Bosentan Drug-Drug Interaction: A Word of Caution Regarding the Most Common Combination Therapy in Children with Advanced Pulmonary Arterial Hypertension.
Topics: Bosentan; Child; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Sildenafil Citrate | 2018 |
Bosentan and antiretroviral therapy in an HIV/HBV/HCV coinfected Chinese patient with HIV-related pulmonary arterial hypertension.
Topics: Adult; Anti-HIV Agents; Bosentan; Familial Primary Pulmonary Hypertension; Hepacivirus; Hepatitis B virus; HIV; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2013 |
Idiopathic pulmonary arterial hypertension.
Topics: Aminorex; Antihypertensive Agents; Appetite Depressants; Bosentan; Dasatinib; Epoprostenol; Familial Primary Pulmonary Hypertension; Fenfluramine; Genetic Predisposition to Disease; Humans; Hypertension, Pulmonary; Iloprost; Phenylpropionates; Piperazines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridazines; Pyrimidines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Thiazoles; Vasodilator Agents | 2013 |
Effectiveness of bosentan in a case of pulmonary arterial hypertension associated with myelodysplastic syndrome.
Topics: Aged; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Myelodysplastic Syndromes; Sulfonamides; Treatment Outcome | 2014 |
Recurrent gastrointestinal bleeding in a patient with Eisenmenger syndrome using bosentan.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Familial Primary Pulmonary Hypertension; Female; Gastrointestinal Hemorrhage; Humans; Hypertension, Pulmonary; Recurrence; Sulfonamides; Young Adult | 2013 |
Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Norepinephrine; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasoconstriction | 2014 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension.
Topics: Bosentan; Cardiovascular Agents; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Fingers; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Treatment Outcome | 2014 |
Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
Topics: Adolescent; Age Factors; Antihypertensive Agents; Bosentan; Child; Cohort Studies; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Netherlands; Piperazines; Purines; Secondary Care Centers; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Autoimmune hepatitis in a patient with pulmonary arterial hypertension treated with endothelin receptor antagonists.
Topics: Biopsy; Bosentan; Diagnosis, Differential; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hepatitis, Autoimmune; Humans; Middle Aged; Phenylpropionates; Pyridazines; Sulfonamides; Tomography, X-Ray Computed; Ultrasonography, Doppler, Duplex | 2014 |
Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arteriovenous Malformations; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Mutation; Pedigree; Piperazines; Pulmonary Artery; Pulmonary Veins; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Cause of Death; Child; Connective Tissue Diseases; Drug Therapy, Combination; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Treatment Outcome; Vasodilator Agents; Young Adult | 2015 |
Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2015 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Australia; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Registries; Sulfonamides; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Monocrotaline; Piperazines; Pulmonary Artery; Purines; Rats; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2010 |
Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
Topics: Adult; Aged; Australia; Bosentan; Cooperative Behavior; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Piperazines; Prospective Studies; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Young Adult | 2011 |
Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension.
Topics: Acetylcholine; Aged; Antihypertensive Agents; Arginine; Bosentan; Endothelium, Vascular; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Nitroprusside; omega-N-Methylarginine; Pulmonary Artery; Sulfonamides; Ultrasonography | 2010 |
Successful bosentan therapy for pulmonary arterial hypertension associated with hereditary hemorrhagic telangiectasia.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Bosentan; Echocardiography, Doppler; Endothelin Receptor Antagonists; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Recovery of Function; Sulfonamides; Telangiectasia, Hereditary Hemorrhagic; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children.
Topics: Adolescent; Algorithms; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Disease Progression; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pulmonary Medicine; Retrospective Studies; Sulfonamides; Treatment Outcome | 2011 |
[Using nonselective endothelin receptor antagonist in idiopathic pulmonary hypertension].
Topics: Adult; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome | 2010 |
Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension.
Topics: Adolescent; Age Factors; Aryl Hydrocarbon Hydroxylases; Asian People; Bayes Theorem; Body Weight; Bosentan; Child; Child, Preschool; Computer Simulation; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Familial Primary Pulmonary Hypertension; Female; Genotype; Heart Failure; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Liver-Specific Organic Anion Transporter 1; Male; Models, Biological; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperazines; Polymorphism, Single Nucleotide; Purines; Sildenafil Citrate; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Sulfones | 2011 |
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Muscle, Smooth, Vascular; Nifedipine; Nitric Oxide Synthase Type III; Piperazines; Pulmonary Artery; Purines; Receptor, Endothelin A; Receptor, Endothelin B; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2011 |
[Successful bosentan therapy in a case of pulmonary arterial hypertention developed during immunosuppressive therapy for lupus nephritis].
Topics: Adult; Antihypertensive Agents; Bosentan; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Prednisolone; Sulfonamides; Treatment Outcome | 2011 |
Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Survival Rate; Time Factors | 2013 |
[Treatment of idiopathic pulmonary arterial hypertension].
Topics: Adult; Airway Resistance; Antihypertensive Agents; Bosentan; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Lung Volume Measurements; Male; Middle Aged; Oxygen Consumption; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Retrospective Studies; Sulfonamides; Young Adult | 2013 |
Pulmonary hypertension presenting with apnea, cyanosis, and failure to thrive in a young child.
Topics: Antihypertensive Agents; Apnea; Biopsy; Bosentan; Cyanosis; Failure to Thrive; Familial Primary Pulmonary Hypertension; Fatal Outcome; Female; Hemangioma, Capillary; Humans; Hypertension, Pulmonary; Infant; Lung; Lung Neoplasms; Radiography, Thoracic; Sulfonamides | 2011 |
Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Pulmonary Emphysema; Sulfonamides; Vasodilator Agents | 2011 |
VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension.
Topics: Animals; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Monocrotaline; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Sulfonamides; Vasoactive Intestinal Peptide | 2011 |
Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.
Topics: Adult; Algorithms; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Hospitals, Pediatric; Humans; Hypertension, Pulmonary; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prevalence; Pyridazines; Sulfonamides; Texas; Transition to Adult Care | 2011 |
The management of Eisenmenger syndrome in the modern treatment era: a case report.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Drug Therapy, Combination; Eisenmenger Complex; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Iron, Dietary; Piperazines; Purines; Quality of Life; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
"Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Iloprost; Lung Transplantation; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2011 |
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
Topics: Adult; Antihypertensive Agents; Bosentan; Case-Control Studies; Drug Therapy, Combination; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Injections, Intravenous; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2012 |
Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Bosentan; Endothelin-1; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome | 2013 |
Pulmonary arterial hypertension during systemic lupus.
Topics: Adult; Bosentan; Cyclophosphamide; Familial Primary Pulmonary Hypertension; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Middle Aged; Mycophenolic Acid; Steroids; Sulfonamides; Treatment Outcome | 2012 |
Curing HIV-associated pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; HIV Infections; Humans; Hypertension, Pulmonary; Middle Aged; Remission Induction; Sulfonamides | 2012 |
Abnormal pulmonary artery stiffness in pulmonary arterial hypertension: in vivo study with intravascular ultrasound.
Topics: Aged; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Wedge Pressure; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional; Vascular Stiffness | 2012 |
Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Cohort Studies; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Pyridazines; Retrospective Studies; Sulfonamides | 2013 |
Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sulfonamides; Thiophenes; Treatment Outcome; Vascular Resistance | 2013 |
Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Drug Interactions; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Receptor, Endothelin B; Sulfonamides | 2012 |
Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
Topics: Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Sulfonamides; Thiophenes; Vascular Resistance | 2013 |
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Topics: Animals; Bosentan; Calcium; CHO Cells; Clinical Trials, Phase III as Topic; Cricetinae; Endothelin Receptor Antagonists; Endothelin-1; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Inositol Phosphates; Myocytes, Smooth Muscle; Phenylpropionates; Pulmonary Artery; Pyridazines; Pyrimidines; Receptors, Endothelin; Sulfonamides | 2012 |
Has the 6-min walk distance run its course?
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Sulfonamides | 2012 |
Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study.
Topics: Aged; Antihypertensive Agents; Bosentan; Case-Control Studies; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Fingers; Humans; Hypertension, Pulmonary; Male; Middle Aged; Retrospective Studies; Scleroderma, Systemic; Skin Ulcer; Sulfonamides; Time Factors; Treatment Outcome; Vascular Diseases | 2013 |
Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Prospective Studies; Sulfonamides; Time Factors | 2013 |